Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 2/3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 151Lung Neoplasms 34Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Neoplasms 9Neoplasm Metastasis 9Mesothelioma 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Mesothelioma, Malignant 4Lung Diseases 4Carcinoma, Bronchogenic 4Non-squamous Non-small Cell Lung Cancer 3Non-Squamous Non-Small Cell Lung Cancer 3Neoplasms by Site 3NSCLC 3Bronchial Neoplasms 3Adenocarcinoma 3Recurrence 2Non-Squamous Non-small Cell Lung Cancer 2Non Small Cell Lung Carcinoma NSCLC 2Head and Neck Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Pemetrexed × Clear all
NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Clovis Oncology, Inc.

Phase 3 Terminated
149 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT00095199 2012-10-15

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Eli Lilly and Company

Phase 3 Completed
939 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡